ABBV vs GEV: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and GE Vernova Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-24.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
GE Vernova Inc. · Industrials
$951.82
+35.4% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
GEV has more upside to fair value
(+35.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
GEV |
| Current Price |
$261.70 |
$951.82 |
| Fair Value Estimate |
$259.04 |
$1,288.67 |
| Upside to Fair Value |
-1.0%
|
+35.4%
|
| Market Cap |
$462.4B |
$253.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
28.2x
|
| Price / Sales |
7.2x
|
6.1x
|
| Price / FCF |
23.6x
|
20.5x
|
| Revenue Growth YoY |
+10.2%
|
+21.9%
|
| Gross Margin |
71.5%
|
20.2%
|
| Operating Margin |
29.3%
|
4.4%
|
| Return on Equity |
-136.5%
|
83.4%
|
| Dividend Yield |
2.61% |
0.18% |
| FCF Yield |
4.25%
|
4.88%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
GE Vernova is an energy equipment and infrastructure enterprise spanning Power (gas, nuclear, hydro, steam), Wind (offshore and onshore turbines), and Electrification (grid, power conversion, solar and storage), with 78,000 employees and a Cambridge, Massachusetts headquarters. The business quality is high on the strength of an installed base that generates roughly 25% of the world's electricity,…
Accumulation Zones
| Metric |
ABBV |
GEV |
| Zone Low |
$194.28 |
$966.50 |
| Zone High |
$220.18 |
$1,095.37 |
| In Buy Zone? |
No
|
Yes
|